Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Draft Genome Sequence of Duganella sp. Strain DN04, Isolated from Cultivated Soil.

Raths R, Peta V, Bücking H.

Microbiol Resour Announc. 2019 Aug 8;8(32). pii: e00848-19. doi: 10.1128/MRA.00848-19.

2.

Draft Genome Sequence of Massilia sp. Strain MC02, Isolated from a Sandy Loam Maize Soil.

Raths R, Peta V, Bücking H.

Microbiol Resour Announc. 2019 Aug 8;8(32). pii: e00410-19. doi: 10.1128/MRA.00410-19.

3.

Draft Genome Sequence of Massilia sp. Strain ONC3, a Novel Bacterial Species of the Oxalobacteraceae Family Isolated from Garden Soil.

Peta V, Raths R, Bücking H.

Microbiol Resour Announc. 2019 Aug 8;8(32). pii: e00377-19. doi: 10.1128/MRA.00377-19.

4.

LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V; HECAM-FibroFrance Group.

Aliment Pharmacol Ther. 2019 Feb;49(3):308-320. doi: 10.1111/apt.15082. Epub 2018 Dec 19.

5.

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.

Poynard T, Peta V, Munteanu M, Charlotte F, Ngo Y, Ngo A, Perazzo H, Deckmyn O, Pais R, Mathurin P, Myers R, Loomba R, Ratziu V; FLIP consortium, the FibroFrance-CPAM group, the FibroFrance-Obese group, and the Selonsertib group.

Eur J Gastroenterol Hepatol. 2019 Mar;31(3):393-402. doi: 10.1097/MEG.0000000000001304.

6.

Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

Munteanu M, Pais R, Peta V, Deckmyn O, Moussalli J, Ngo Y, Rudler M, Lebray P, Charlotte F, Thibault V, Lucidarme O, Ngo A, Imbert-Bismut F, Housset C, Thabut D, Ratziu V, Poynard T; FibroFrance Group.

Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127. doi: 10.1111/apt.14990. Epub 2018 Oct 17.

7.

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

Peta V, Tse C, Perazzo H, Munteanu M, Ngo Y, Ngo A, Ramanujam N, Verglas L, Mallet M, Ratziu V, Thabut D, Rudler M, Thibault V, Schuppe-Koistinen I, Bonnefont-Rousselot D, Hainque B, Imbert-Bismut F, Merz M, Kullak-Ublick G, Andrade R, van Boemmel F, Schott E, Poynard T; Drug Induced Liver Injury- Groupe Hospitalier Pitié-Salpêtrière; Drug Induced Liver Group of the Injury Safer and Faster Evidence-based Translation consortium.

PLoS One. 2017 Dec 29;12(12):e0189436. doi: 10.1371/journal.pone.0189436. eCollection 2017.

8.

Screening studies of transient elastography and FibroTest in the general population.

Poynard T, Peta V, Pollo-Flores P, Munteanu M, Ratziu V.

Lancet Gastroenterol Hepatol. 2017 Apr;2(4):246. doi: 10.1016/S2468-1253(17)30034-1. Epub 2017 Mar 9. No abstract available.

PMID:
28404148
9.

Laboratory Tests for Diagnosis of Alcoholic Liver Disease.

Peta V, Elaribi D, Abenavoli L.

Rev Recent Clin Trials. 2016;11(3):180-4. Review.

PMID:
27515961
10.

Nutritional profile of adult patients with celiac disease.

Abenavoli L, Delibasic M, Peta V, Turkulov V, De Lorenzo A, Medić-Stojanoska M.

Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4285-92. Review.

11.

Adiponectin serum level in chronic hepatitis C infection and therapeutic profile.

Peta V, Torti C, Milic N, Focà A, Abenavoli L.

World J Hepatol. 2015 Jan 27;7(1):44-52. doi: 10.4254/wjh.v7.i1.44. Review.

12.

Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease.

Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, Foti D, Gulletta E, Luzza F.

Expert Rev Gastroenterol Hepatol. 2015 Apr;9(4):519-27. doi: 10.1586/17474124.2015.1004312. Epub 2015 Jan 23.

PMID:
25617046
13.

Role of endoscopy in management of gastrointestinal complications of portal hypertension.

Luigiano C, Iabichino G, Judica A, Virgilio C, Peta V, Abenavoli L.

World J Gastrointest Endosc. 2015 Jan 16;7(1):1-12. doi: 10.4253/wjge.v7.i1.1. Review.

14.
15.

Role of adipokines and cytokines in non-alcoholic fatty liver disease.

Abenavoli L, Peta V.

Rev Recent Clin Trials. 2014;9(3):134-40. Review.

PMID:
25514909
16.

Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S.

World J Gastroenterol. 2014 Dec 7;20(45):16831-40. doi: 10.3748/wjg.v20.i45.16831. Review.

17.

Functional and molecular effects of mercury compounds on the human OCTN1 cation transporter: C50 and C136 are the targets for potent inhibition.

Galluccio M, Pochini L, Peta V, Iannì M, Scalise M, Indiveri C.

Toxicol Sci. 2015 Mar;144(1):105-13. doi: 10.1093/toxsci/kfu259. Epub 2014 Dec 8.

PMID:
25490951
18.

Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.

Abenavoli L, Masarone M, Peta V, Milic N, Kobyliak N, Rouabhia S, Persico M.

World J Gastroenterol. 2014 Nov 7;20(41):15233-40. doi: 10.3748/wjg.v20.i41.15233. Review.

19.

Inhibition of the OCTN2 carnitine transporter by HgCl2 and methylmercury in the proteoliposome experimental model: insights in the mechanism of toxicity.

Pochini L, Peta V, Indiveri C.

Toxicol Mech Methods. 2013 Feb;23(2):68-76. doi: 10.3109/15376516.2012.719166. Epub 2012 Oct 18.

PMID:
22900493
20.

Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).

Sharma R, Majer F, Peta VK, Wang J, Keaveney R, Kelleher D, Long A, Gilmer JF.

Bioorg Med Chem. 2010 Sep 15;18(18):6886-95. doi: 10.1016/j.bmc.2010.07.030. Epub 2010 Jul 19.

PMID:
20713311

Supplemental Content

Support Center